Millennium: The Takeda Oncology Co. and its Japanese parent said Wednesday that European regulators have granted conditional marketing authorization for Adcetris, a drug for some forms of lymphoma, a general term for cancers of the lymphatic system.
In a press release, Takeda Pharmaceutical Co. said it intends to launch Adcetris in Europe in coming weeks. (Takeda bought Cambridge-based Millennium in 2008 for $8.8 billion.)
Specifically, Millennium and Takeda said the European Commission has granted conditional marketing authorization for Adcetris to treat adults with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Since 2009, Millennium has been working on Adcetris with Seattle Genetics, (which also issued a press release Wednesday). In August 2011, the drug received Food and Drug Administration approval to be marketed in the United States.